Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey

Sukran Kose; Gursel Ersan; Suheyla Serin Senger; Gulsun Akincioglu; Melda Ulusoy; Gulgun Akkoclu

doi:https://doi.org/10.5799/ahinjs.02.2012.03.0050

Article Details

Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey

Authors:

Sukran Kose | Gursel Ersan | Suheyla Serin Senger | Gulsun Akincioglu | Melda Ulusoy | Gulgun Akkoclu

Publisher:

Sağlık Araştırmaları Derneği

Journal:

Journal of Microbiology and Infectious Diseases 2012 Vol.2 Issue 03, pp.87-92

Document Type:

Article

Publication Date:

8/2012

Document Language:

English

Document ID (Org No.):

2000487999

Frequency:

Quarterly

eISSN:

2146-9369

pISSN:

2146-3158

DOI:

https://doi.org/10.5799/ahinjs.02.2012.03.0050

Abstract:

 

Objectives: The goal of therapy in chronic hepatitis B infection (CHB) is to impede liver injury by suppressing viral rep-    	lication. The study was aimed to determine the eficacy of tenofovir (TDF) in CHB infection for 48 weeks.     	Materials and methods: We retrospectively analyzed the data of 45 CHB patients treated by tenofovir. The patients     	were divided into two groups based on their hepatitis B e antigen status (HBeAg). Those who were eligible to therapy     	received TDF 300 mg once daily for 48 weeks. Serum alanine aminotransferase levels (ALT), hepatitis B virus DNA (HBV     	DNA), and viral serological markers were checked at three-month intervals. Liver biopsy scores were determined in all     	patients.     	Results: The mean age ± standard deviation  (SD) was 35.8 ± 17.0 years, 26  (57.8 %) were male, and seven patients     	(15.5%) were treatment-experienced by a nucleos(t)ide analogue before TDF. HBeAg was positive in 17 (37.8%) patients.     	At week 48 among HBeAg positive (HBeAg +) patients\' biochemical and virological response rates at month-3, -6 and     	-12 were 64.7%, and 100%, 70.6%, and 94.1%, and 88.2%, and 64.7%, respectively. The serological response in HBeAg     	+ patients was 29.4%. For HBeAg negative (HBeAg -) patients; biochemical, and virological response rates were 64.3%,     	and 96.4% at month 3; 82.1%, and 96.4% at month 6; and 100%, and 85.7% at month 12, respectively. At week 48 both     	groups had signiicant virological response (p<0.001).     	Conclusion: Treatment in CHB with TDF leads to HBV DNA suppression without evident resistance for 48-week, and is     	well tolerated.

Article Details

Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey

Authors: Sukran Kose | Gursel Ersan | Suheyla Serin Senger | Gulsun Akincioglu | Melda Ulusoy | Gulgun Akkoclu

Publisher: Sağlık Araştırmaları Derneği

Journal: Journal of Microbiology and Infectious Diseases 2012 Vol.2 Issue 03, pp.87-92

Document Type: Article

Publication Date: 8/2012

Document Language: English

Document ID (Org No.): 2000487999

Frequency: Quarterly

eISSN: 2146-9369

pISSN: 2146-3158

DOI: https://doi.org/10.5799/ahinjs.02.2012.03.0050

Issues

Authors:

Sukran Kose | Gursel Ersan | Suheyla Serin Senger | Gulsun Akincioglu | Melda Ulusoy | Gulgun Akkoclu

Publisher:

Sağlık Araştırmaları Derneği

Journal:

Journal of Microbiology and Infectious Diseases 2012 Vol.2 Issue 03, pp.87-92

Document Type:

Article

Publication Date:

8/2012

Document Language:

English

Document ID (Org No.):

2000487999

Frequency:

Quarterly

eISSN:

2146-9369

pISSN:

2146-3158

DOI:

https://doi.org/10.5799/ahinjs.02.2012.03.0050